Results 81 to 90 of about 14,336,962 (399)

Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model

Molecular Oncology, EarlyView.
Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells
Daniel J. Smit, Thais Pereira‐Veiga, Helena Brauer, Michael Horn, Paula Nissen, Thomas Mair, Bente Siebels, Hannah Voß, Ruimeng Zhuang, Marie‐Therese Haider, Desiree Loreth, Margarita Iskhakova, Bele Lindemann, Julian Kött, Laure Cayrefourcq, Jasmin Wellbrock, Hartmut Schlüter, Klaus Pantel, Catherine Alix‐Panabières, Manfred Jücker   +19 more
wiley   +1 more source

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?

Journal of Blood Medicine, 2017
Kenneth Lieuw1,2 1Department of Pediatrics, Walter Reed National Military Medical Center, 2Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA Abstract: Hemophilia A (HA) is a common bleeding disorder caused ...
Lieuw K
doaj  

Repression of factor VIII inhibitor development with apoptotic factor VIII-expressing embryonic stem cells

Hematology Reports, 2013
Development of factor VIII (fVIII)-neutralizing antibodies, called inhibitors, is a challenging problem in the management of hemophilia A patients. We explored the possibility of pretreatment with apoptotic fVIII-expressing embryonic stem (ES) cells to ...
Yoshihiko Sakurai, Shogo Kasuda, Kohei Tatsumi, Tomohiro Takeda, Junko Kato, Atsushi Kubo, Midori Shima   +6 more
doaj   +1 more source

Hemostasis biomarkers and incident cognitive impairment: the REGARDS study [PDF]

, 2018
Essentials Cognitive disorders are increasing and vascular risk factors play a role in this. We performed a nested case control study of hemostasis biomarkers and cognitive impairment (CI). Higher baseline fibrinogen, factor VIII and D-dimer were related
Callas, P.W., Cushman, M., Gillett, S.R., Letter, A.J., McClure, L.A., Thacker, E.L., Unverzagt, F.W., Wadley, V.G.   +7 more
core   +1 more source

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.

Blood, 2014
This phase 3 pivotal study evaluated the safety, efficacy, and pharmacokinetics of a recombinant FVIII Fc fusion protein (rFVIIIFc) for prophylaxis, treatment of acute bleeding, and perioperative hemostatic control in 165 previously treated males aged ...
J. Mahlangu, J. Powell, M. Ragni, P. Chowdary, N. Josephson, I. Pabinger, H. Hanabusa, N. Gupta, R. Kulkarni, P. Fogarty, D. Perry, A. Shapiro, K. Pasi, Shashikant Apte, I. Nestorov, Haiyan Jiang, Shuanglian Li, S. Neelakantan, L. Cristiano, J. Goyal, J. Sommer, J. Dumont, Nigel Dodd, Karen Nugent, G. Vigliani, A. Luk, Aoife Brennan, Glenn F Pierce   +27 more
semanticscholar   +1 more source

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Principles of care for the diagnosis and treatment of von Willebrand disease

Haematologica, 2013
Von Willebrand disease is a common autosomal inherited bleeding disorder caused by quantitative or qualitative defects of von Willebrand factor, a multi-adhesive protein that binds platelets to exposed subendothelium and carries factor VIII in ...
Giancarlo Castaman, Anne Goodeve, Jeroen Eikenboom   +2 more
doaj   +1 more source

Suppression of an Antibody to Factor VIII by a Combination of Factor VIII and Cyclophosphamide [PDF]

Blood, 1971
Abstract A 54-year-old woman with a 20-year history of generalized, severe psoriasis presented with diffuse ecchymoses, melena, and vaginal bleeding. The whole blood clotting time was 59 minutes and the plasma factor VIII concentration was less than 1 per cent of normal.
openaire   +3 more sources

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

“Prevalence of Inhibitors in Hemophilia Patients and its Clinical Implications”: A Study of 276 Patients in Western India

Global Journal of Transfusion Medicine, 2019
Introduction: Hemophilia is an X-linked congenital bleeding disorder caused by a deficiency of coagulation factor VIII (FVIII) in hemophilia A (HA) or factor IX (FIX) in hemophilia B (HB).
Sangita Darshan Shah, Tarak R Patel, Nidhi M Bhatnagar, Maitrey D Gajjar, Mamta Chintan Shah, Sujata Tripathi   +5 more
doaj   +1 more source